‘Lipiodol’ takes drug price negotiation after being designated as shortage-prevented drug

Published: 2018-06-14 15:02:38

Updated: 2018-06-14 15:02:38

‘Lipiodol’ which has recently caused controversy with its supply suspension will get on a drug price negotiation after being designated as a shortage-prevented drug.

‘Erbitux’ which ended the drug price negotiation with the National Health Insurance Service(NHIS) will be applied with the risk-sharing agreement by June 2022 for the current drug price.

At Health Insurance Review and Assessment ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.